Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 19.5% in the ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing ...

NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

Biohaven (NYSE:BHVN – Free Report) had its price objective lowered by Morgan Stanley from $69.00 to $63.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Highlights,Institutional firms have modified their holdings in Biohaven Ltd., contributing to shifts in stock ownership.,Biohaven’s stock performance reflects fluctuations, with market participation ...

Biohaven Ltd. (NYSE:BHVN) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurological and neuropsychiatric diseases. The company’s portfolio ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed ...

Three of VB's underlying holdings with notable upside to their analyst target prices are CG Oncology Inc (Symbol: CGON), Denali Therapeutics Inc (Symbol: DNLI), and Biohaven Ltd (Symbol ...